Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy

Yuh Min Chen, Reury Perng Perng, Wei Chun Lin, Hsiao Wei Wu, Chun Ming Tsai, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We conducted a phase II study of docetaxel and gemcitabine chemotherapy in patients with non-small-cell lung cancer (NSCLC) who had not responded to previous chemotherapy, to assess the response to and toxicity of this combination chemotherapy. Thirty-six patients were enrolled from June 1999 to December 1999. Treatment consisted of docetaxel 30 mg/m2 and gemcitabine 800 mg/m2 intravenous infusion on days 1 and 8 every 3 weeks. One hundred forty-six cycles of treatment were given, with a median of four cycles (range, 1-8 cycles). All patients were evaluable for toxicity profile and response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (25%) during treatment. Febrile neutropenia occurred in 2 patients (5.6%). Grade III or IV thrombocytopenia occurred in 6 patients (16.7%). Reversible fluid retention occurred in 9 patients (25%). Grade IV pulmonary toxicity (interstitial pneumonitis) occurred in two patients, and both died. Other toxicities were few and mild in severity. After two cycles of treatment, 13 patients (36.1%) had a partial response (95% CI 20.3-51.9%). There was no significant difference in the response rate among patients who had responded to previous chemotherapy or not. The median time to disease progression was 3.8 months, and the median survival was 6.9 months. Median survival was 7.1 and 4.9 months in patients receiving docetaxel and gemcitabine as second-line and greater than or equal to third-line chemotherapy, respectively. In conclusion, docetaxel and gemcitabine salvage chemotherapy produces a high response rate and a relatively mild toxicity profile in NSCLC. However, the issue of interstitial pneumonitis should be of concern.

Original languageEnglish
Pages (from-to)509-512
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume25
Issue number5
DOIs
Publication statusPublished - Oct 1 2002
Externally publishedYes

Fingerprint

docetaxel
gemcitabine
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Drug Therapy
Interstitial Lung Diseases
Febrile Neutropenia

Keywords

  • Cisplatin
  • Docetaxel
  • Gemcitabine
  • Non-small-cell lung cancer
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. / Chen, Yuh Min; Perng, Reury Perng; Lin, Wei Chun; Wu, Hsiao Wei; Tsai, Chun Ming; Whang-Peng, Jacqueline.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 25, No. 5, 01.10.2002, p. 509-512.

Research output: Contribution to journalArticle

@article{6cf22156fa4943fca27ad673ccf84abb,
title = "Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy",
abstract = "We conducted a phase II study of docetaxel and gemcitabine chemotherapy in patients with non-small-cell lung cancer (NSCLC) who had not responded to previous chemotherapy, to assess the response to and toxicity of this combination chemotherapy. Thirty-six patients were enrolled from June 1999 to December 1999. Treatment consisted of docetaxel 30 mg/m2 and gemcitabine 800 mg/m2 intravenous infusion on days 1 and 8 every 3 weeks. One hundred forty-six cycles of treatment were given, with a median of four cycles (range, 1-8 cycles). All patients were evaluable for toxicity profile and response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (25{\%}) during treatment. Febrile neutropenia occurred in 2 patients (5.6{\%}). Grade III or IV thrombocytopenia occurred in 6 patients (16.7{\%}). Reversible fluid retention occurred in 9 patients (25{\%}). Grade IV pulmonary toxicity (interstitial pneumonitis) occurred in two patients, and both died. Other toxicities were few and mild in severity. After two cycles of treatment, 13 patients (36.1{\%}) had a partial response (95{\%} CI 20.3-51.9{\%}). There was no significant difference in the response rate among patients who had responded to previous chemotherapy or not. The median time to disease progression was 3.8 months, and the median survival was 6.9 months. Median survival was 7.1 and 4.9 months in patients receiving docetaxel and gemcitabine as second-line and greater than or equal to third-line chemotherapy, respectively. In conclusion, docetaxel and gemcitabine salvage chemotherapy produces a high response rate and a relatively mild toxicity profile in NSCLC. However, the issue of interstitial pneumonitis should be of concern.",
keywords = "Cisplatin, Docetaxel, Gemcitabine, Non-small-cell lung cancer, Salvage chemotherapy",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Lin, {Wei Chun} and Wu, {Hsiao Wei} and Tsai, {Chun Ming} and Jacqueline Whang-Peng",
year = "2002",
month = "10",
day = "1",
doi = "10.1097/00000421-200210000-00017",
language = "English",
volume = "25",
pages = "509--512",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Lin, Wei Chun

AU - Wu, Hsiao Wei

AU - Tsai, Chun Ming

AU - Whang-Peng, Jacqueline

PY - 2002/10/1

Y1 - 2002/10/1

N2 - We conducted a phase II study of docetaxel and gemcitabine chemotherapy in patients with non-small-cell lung cancer (NSCLC) who had not responded to previous chemotherapy, to assess the response to and toxicity of this combination chemotherapy. Thirty-six patients were enrolled from June 1999 to December 1999. Treatment consisted of docetaxel 30 mg/m2 and gemcitabine 800 mg/m2 intravenous infusion on days 1 and 8 every 3 weeks. One hundred forty-six cycles of treatment were given, with a median of four cycles (range, 1-8 cycles). All patients were evaluable for toxicity profile and response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (25%) during treatment. Febrile neutropenia occurred in 2 patients (5.6%). Grade III or IV thrombocytopenia occurred in 6 patients (16.7%). Reversible fluid retention occurred in 9 patients (25%). Grade IV pulmonary toxicity (interstitial pneumonitis) occurred in two patients, and both died. Other toxicities were few and mild in severity. After two cycles of treatment, 13 patients (36.1%) had a partial response (95% CI 20.3-51.9%). There was no significant difference in the response rate among patients who had responded to previous chemotherapy or not. The median time to disease progression was 3.8 months, and the median survival was 6.9 months. Median survival was 7.1 and 4.9 months in patients receiving docetaxel and gemcitabine as second-line and greater than or equal to third-line chemotherapy, respectively. In conclusion, docetaxel and gemcitabine salvage chemotherapy produces a high response rate and a relatively mild toxicity profile in NSCLC. However, the issue of interstitial pneumonitis should be of concern.

AB - We conducted a phase II study of docetaxel and gemcitabine chemotherapy in patients with non-small-cell lung cancer (NSCLC) who had not responded to previous chemotherapy, to assess the response to and toxicity of this combination chemotherapy. Thirty-six patients were enrolled from June 1999 to December 1999. Treatment consisted of docetaxel 30 mg/m2 and gemcitabine 800 mg/m2 intravenous infusion on days 1 and 8 every 3 weeks. One hundred forty-six cycles of treatment were given, with a median of four cycles (range, 1-8 cycles). All patients were evaluable for toxicity profile and response rate. The major toxicity was myelosuppression. Grade III or IV neutropenia occurred in 9 patients (25%) during treatment. Febrile neutropenia occurred in 2 patients (5.6%). Grade III or IV thrombocytopenia occurred in 6 patients (16.7%). Reversible fluid retention occurred in 9 patients (25%). Grade IV pulmonary toxicity (interstitial pneumonitis) occurred in two patients, and both died. Other toxicities were few and mild in severity. After two cycles of treatment, 13 patients (36.1%) had a partial response (95% CI 20.3-51.9%). There was no significant difference in the response rate among patients who had responded to previous chemotherapy or not. The median time to disease progression was 3.8 months, and the median survival was 6.9 months. Median survival was 7.1 and 4.9 months in patients receiving docetaxel and gemcitabine as second-line and greater than or equal to third-line chemotherapy, respectively. In conclusion, docetaxel and gemcitabine salvage chemotherapy produces a high response rate and a relatively mild toxicity profile in NSCLC. However, the issue of interstitial pneumonitis should be of concern.

KW - Cisplatin

KW - Docetaxel

KW - Gemcitabine

KW - Non-small-cell lung cancer

KW - Salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036794926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036794926&partnerID=8YFLogxK

U2 - 10.1097/00000421-200210000-00017

DO - 10.1097/00000421-200210000-00017

M3 - Article

VL - 25

SP - 509

EP - 512

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -